Group 1: Precision Instruments - The article emphasizes that precision instruments are the cornerstone of modern industry and technology development, with increasing risks from U.S. restrictions [1] - It suggests three main investment lines in China's precision instrument sector: seeking "China's Zeiss" in optical instruments, "China's HP" in electronic measurement instruments, and "China's Thermo Fisher" in analytical instruments [1] Group 2: Chromium Chemicals - The price of metal chromium has significantly increased, with a total price hike of 10,000 yuan per ton since the beginning of 2025, indicating strong demand and supply dynamics [2] - The article recommends investing in leading companies with integrated chromium product layouts due to the favorable market conditions [2] Group 3: Insurance Companies - Insurance companies face challenges in asset-liability matching, with a near 50% allocation to fixed-income assets, leading to risks of interest margin losses [3][4] - The article highlights three strategies for insurance capital to enhance investment returns: participating in private placements, strategic investments, and shareholding strategies [3][4] Group 4: Wind Power - The domestic and international offshore wind power sectors are expected to see sustained growth, with domestic installations projected to exceed 12 GW in 2025, doubling year-on-year [6] - The article suggests focusing on various segments of the offshore wind power supply chain, including turbines, subsea cables, and foundations [6] Group 5: ETF Market - The global ETF market is projected to reach $15.09 trillion by 2024, while China's ETF market remains relatively small and underdeveloped [7] - The article advocates for domestic institutions to innovate product types and enhance liquidity mechanisms to build a sustainable market ecosystem [7]

秦培景｜中信证券 首席策略师 S1010512050004 主题策略｜精密仪器：科技自主柱石，品牌成长良机 精密仪器是现代工业和科技发展的基石。近年来大国竞争日趋激烈，美国对精密仪器 封锁围堵风险提升。研究国内新兴产业发展现状，复盘国际精密仪器巨头崛起经验， 能从多个关键维度帮助我们把握中国精密仪器投资机遇。结合国内精密仪器企业市场 生态，我们建议通过三条主线投资中国精密仪器赛道突围：1）寻找下游应用领域丰 富的光学仪器赛道中的"中国蔡司"；2）寻找受益国内高端制造产业链崛起的电子测 量仪器赛道中的"中国惠普"；3）寻找国产替代弹性十足的分析仪器赛道中的"中国赛 默飞"。 风险因素：中美科技贸易等领域摩擦超预期加剧；宏观经济周期波动风险；科技领域 海外技术迭代速度超预期；技术突破难度较大；市场认知与品牌建设不及预期风险； 资金和人才竞争风险。 王喆｜中信证券 能源与材料产业首席分析师 S1010513110001 铬化工｜金属铬价格跳涨，强烈推荐板块投资机遇 2025年4月18日，振华股份宣布其金属铬产品单吨售价大幅调涨5000元，此前公司已 于2月10日、3月13日连续调涨金属铬单吨售价3000/2000元 ...

Group 1 - The core point of the article highlights the performance and holdings of the Ping An Medical Health Mixed C fund, which has shown significant growth in its net value and returns over various time frames [1] - As of April 21, 2025, the latest net value of the fund is 2.0478 yuan, reflecting a growth of 2.96%. The fund's one-month return is 7.41%, three-month return is 32.95%, and year-to-date return is 32.27% [1] - The fund's top ten stock holdings account for a total of 83.49%, with significant positions in companies such as Kangfang Biotech (9.32%), BeiGene (9.13%), and others [1] Group 2 - The Ping An Medical Health Mixed C fund was established on November 28, 2023, and as of March 31, 2025, it has a total scale of 1.339 billion yuan [1] - The fund manager, Zhou Sicong, has a background in the financial industry, having previously worked at various fund management companies and managing multiple funds before joining Ping An [2]

从中证500质量指数持仓的市场板块来看，上海证券交易所占比67.01%、深圳证券交易所占比32.99%。 从中证500质量指数持仓样本的行业来看，医药卫生占比29.63%、金融占比20.48%、信息技术占比 13.04%、可选消费占比12.50%、通信服务占比10.27%、工业占比6.64%、原材料占比4.85%、能源占比 1.96%、房地产占比0.64%。 资料显示，指数样本每半年度调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下 一交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一个定 期调整日前，权重因子一般固定不变。每次调整的样本数量一般不超过30%。特殊情况下将对指数进行 临时调整。当样本退市时，将其从指数样本中剔除。样本公司发生收购、合并、分拆等情形的处理，参 照计算与维护细则处理。 金融界4月21日消息，上证指数低开高走，中证500质量指数 (500质量，932432)报3134.91点。 数据统计显示，中证500质量指数近一个月下跌4.63%，近三个月上涨2.51%，年至今上涨2.95%。 据了解，中证500质量指数从中证500指数样本中选取 ...

截至2025年4月18日 10:56，港股医药ETF(159718)上涨0.30%，最新价报0.67元。拉长时间看，截至2025年4月17日，港股医药ETF近1周累计上涨4.19%，涨 幅排名可比基金1/4。 流动性方面，港股医药ETF盘中换手4.75%，成交1032.30万元。拉长时间看，截至4月17日，港股医药ETF近1周日均成交8710.12万元。 规模方面，港股医药ETF本月以来规模增长1569.02万元，实现显著增长，新增规模位居可比基金1/4。 份额方面，港股医药ETF近2周份额增长5200.00万份，实现显著增长，新增份额位居可比基金1/4。 资金流入方面，港股医药ETF最新资金净流出134.67万元。拉长时间看，近9个交易日内有5日资金净流入，合计"吸金"3300.54万元，日均净流入达366.73万 元。 截至2025年4月18日 10:55，中证医药及医疗器械创新指数(931484)下跌0.49%。成分股方面涨跌互现，华东医药(000963)领涨5.19%，惠泰医疗(688617)上涨 1.43%，艾力斯(688578)上涨0.83%；海思科(002653)领跌5.15%，安图生物(603 ...

Core Viewpoint - ICBC Medical Care Stock (000831) has experienced a decline of 0.12% on April 17, with a latest net value of 2.47 yuan, marking a cumulative drop of 1.2% over three consecutive trading days [1] Group 1: Fund Performance - The fund was established in November 2014, with a total scale of 2.644 billion yuan and a cumulative return of 146.70% since inception [1] - As of the end of 2024, institutional investors hold 0.41 million shares, accounting for 3.55% of total shares, while individual investors hold 11.19 million shares, making up 96.45% of total shares [1] Group 2: Fund Management - Current fund manager Zhao Bei has a master's degree and has been with ICBC Credit Suisse since 2010, serving as the fund manager since November 18, 2014 [2] - The current fund manager Ding Yang holds a doctoral degree and joined ICBC Credit Suisse in December 2017, taking over as fund manager on May 5, 2023 [2] Group 3: Portfolio Holdings - As of December 31, 2024, the top ten holdings of ICBC Medical Care Stock account for a total of 36.38%, with major positions including: - Heng Rui Medicine (9.51%) - WuXi AppTec (5.65%) - Mindray Medical (3.83%) - Yuyue Medical (2.88%) - Betta Pharmaceuticals (2.66%) - BeiGene (2.62%) - Aier Eye Hospital (2.41%) - Baiyang Pharmaceutical (2.33%) - Kelun Pharmaceutical (2.30%) - New Horizon Health (2.19%) [3]

今年以来，创新药板块迎来强势反弹，港股创新药指数年内涨幅一度超过35%，成为今年投资回报最大的主 题之一。多只创新药主题基金更是扎堆跻身今年基金业绩排名前列。 不过，受到海外关税风险持续扰动，叠加外围市场持续大跌抑制风险偏好等综合影响，创新药板块也出现较大 回撤。4月8日，美国总统特朗普甚至放话称，美国将对药品征收关税。 4月9日，港股创新药指数盘中巨震，从开盘的下跌8.6%到收盘的上涨1.05%，盘中拉升近10个百分点。对 此，券商中国记者针对市场关切的问题采访了多家机构。多家机构普遍表示，加征关税对创新药板块影响有 限，看好其中长期投资价值。 创新药主题基金扎堆跻身业绩排名前列。 对此，平安医药精选基金经理周思聪表示，此次特朗普对药品加征关税对创新药基本无影响，创新药出海授权 商业化具备较强韧性。 加征关税对创新药影响有限 长城基金基金经理梁福睿对记者表示，美国拟对药品征收关税，预计对创新药影响有限。根据中国医药保健品 进出口商会数据，2024年中国对美国出口额190.5亿美元，同比增长11.7%，其中西药64.25亿 美元 ；进口额 150.6亿美元，同比下降4.3%，其中西药63.33亿 美元 ，药品 ...

Quantitative Models and Construction Methods 1. Model Name: 250-Day New High Distance Model - **Model Construction Idea**: This model tracks the distance of stock prices or indices from their 250-day high to identify market trends and hotspots. It is based on the premise that stocks or indices near their recent highs tend to exhibit stronger momentum and potential for future gains[10][17]. - **Model Construction Process**: The 250-day new high distance is calculated as: $ 250\ Day\ New\ High\ Distance = 1 - \frac{Close_t}{ts\_max(Close, 250)} $ Where: - $Close_t$ represents the latest closing price - $ts\_max(Close, 250)$ represents the maximum closing price over the past 250 trading days If the latest closing price reaches a new high, the distance is 0. If the price has fallen from the high, the distance is a positive value indicating the degree of decline[10]. - **Model Evaluation**: This model effectively captures momentum and trend-following characteristics, aligning with prior research on the predictive power of stocks near their 52-week highs[10][17]. 2. Model Name: Stable New High Stock Screening Model - **Model Construction Idea**: This model identifies stocks that exhibit stable momentum characteristics, focusing on smooth price paths and consistent new highs. It incorporates factors such as analyst attention, relative strength, and price stability to refine the selection process[23][25]. - **Model Construction Process**: The screening process involves the following steps: - **Analyst Attention**: Stocks must have at least 5 "Buy" or "Overweight" ratings in the past 3 months - **Relative Strength**: Stocks must rank in the top 20% of the market based on 250-day price performance - **Price Path Smoothness**: $ Price\ Path\ Smoothness = \frac{Absolute\ Price\ Change\ Over\ 120\ Days}{Sum\ of\ Daily\ Absolute\ Price\ Changes\ Over\ 120\ Days} $ Stocks with smoother price paths are prioritized - **New High Consistency**: The average 250-day new high distance over the past 120 days is calculated, and stocks with consistent proximity to new highs are selected - **Trend Continuation**: The average 250-day new high distance over the past 5 days is calculated, and the top 50 stocks are chosen based on this metric[23][25]. - **Model Evaluation**: This model emphasizes the temporal stability of momentum, leveraging smooth price paths and consistent trends to enhance predictive power[23][25]. --- Backtesting Results of Models 1. 250-Day New High Distance Model - **Indices' 250-Day New High Distance**: - Shanghai Composite Index: 3.97% - Shenzhen Component Index: 7.72% - CSI 300: 8.01% - CSI 500: 6.55% - CSI 1000: 5.20% - CSI 2000: 6.32% - ChiNext Index: 16.55% - STAR 50 Index: 8.64%[11][12][14] 2. Stable New High Stock Screening Model - **Selected Stocks**: 29 stocks were identified, including Wolong Electric, Newland, and Eilis. - **Sector Distribution**: - Manufacturing: 8 stocks (e.g., machinery) - Technology: 8 stocks (e.g., electronics) - Other sectors: Financials, healthcare, etc.[26][30][32] --- Quantitative Factors and Construction Methods 1. Factor Name: 250-Day New High Distance - **Factor Construction Idea**: This factor measures the relative position of a stock's price to its 250-day high, serving as a momentum indicator[10]. - **Factor Construction Process**: $ 250\ Day\ New\ High\ Distance = 1 - \frac{Close_t}{ts\_max(Close, 250)} $ - $Close_t$: Latest closing price - $ts\_max(Close, 250)$: Maximum closing price over the past 250 trading days[10]. - **Factor Evaluation**: This factor is simple yet effective in capturing momentum trends, aligning with established research on the predictive power of stocks near their recent highs[10][17]. 2. Factor Name: Price Path Smoothness - **Factor Construction Idea**: This factor evaluates the stability of a stock's price movement over time, favoring stocks with smoother trajectories[23]. - **Factor Construction Process**: $ Price\ Path\ Smoothness = \frac{Absolute\ Price\ Change\ Over\ 120\ Days}{Sum\ of\ Daily\ Absolute\ Price\ Changes\ Over\ 120\ Days} $ Stocks with higher smoothness scores are prioritized[23]. - **Factor Evaluation**: This factor highlights the importance of temporal stability in momentum strategies, reducing noise from volatile price movements[23]. --- Backtesting Results of Factors 1. 250-Day New High Distance Factor - **Indices' 250-Day New High Distance**: - Shanghai Composite Index: 3.97% - Shenzhen Component Index: 7.72% - CSI 300: 8.01% - CSI 500: 6.55% - CSI 1000: 5.20% - CSI 2000: 6.32% - ChiNext Index: 16.55% - STAR 50 Index: 8.64%[11][12][14] 2. Price Path Smoothness Factor - **Selected Stocks**: 29 stocks were identified, including Wolong Electric, Newland, and Eilis. - **Sector Distribution**: - Manufacturing: 8 stocks (e.g., machinery) - Technology: 8 stocks (e.g., electronics) - Other sectors: Financials, healthcare, etc.[26][30][32]

Core Viewpoint - The article highlights the increasing trend of innovative drug companies in China achieving profitability through product sales rather than one-time business development (BD) transactions, with examples including Innovent Biologics and others focusing on both domestic and international markets [1][2]. Group 1: Company Performance - On March 26, 2024, Innovent Biologics reported a revenue of 9.422 billion yuan, a year-on-year increase of 51.8%, and reduced its annual loss from 1.028 billion yuan to 94.631 million yuan, a decrease of 90.8% [2]. - The company achieved its first positive Non-IFRS profit and Non-IFRS EBITDA of 332 million yuan and 412 million yuan, respectively [2]. - The stock price of Innovent Biologics surged by 17.41% to close at 45.850 HKD per share, with a market capitalization of 75.11 billion HKD [3]. Group 2: Revenue Breakdown - Product revenue reached 8.228 billion yuan, up 43.6%, while licensing fee income doubled from 447 million yuan to 1.1 billion yuan [4]. - Despite significant revenue growth, the company still could not cover operational costs and expenses solely from sales revenue in 2024, indicating reliance on increased licensing fee income for reduced losses [4][5]. Group 3: Future Prospects - Innovent Biologics anticipates improvement in 2025 as several drugs, including lung cancer and hematological malignancy treatments, have been approved for market entry [5]. - The company aims to achieve 20 billion yuan in product revenue by 2027 and has set a goal to have five pipelines enter global multi-center Phase III clinical trials by 2030 [2][5]. - The establishment of a cardiovascular and metabolic (CVM) division is underway, with a focus on diverse marketing strategies and building a consumer-facing brand image [6]. Group 4: Strategic Collaborations and Market Expansion - Innovent Biologics formed a strategic partnership with Meinian Health focusing on precise interventions for overweight patients with fatty liver [7]. - The company has engaged in BD transactions, including a notable deal with Roche for the exclusive rights to develop, produce, and commercialize IBI3009, a targeted ADC for small cell lung cancer, with an upfront payment of 80 million USD and potential milestone payments of up to 1 billion USD [7][8]. - Innovent plans to expand clinical research from China to key markets like the US, with ongoing studies for innovative therapies [8].

Group 1 - The core viewpoint is that the healthcare ETF Taikang (159760) has seen a 1.75% increase, driven by a recovering macroeconomic environment, which is expected to boost the growth rate of healthcare service revenues [1] - The Taikang healthcare ETF closely tracks the National Index of Public Health and Healthcare, which reflects the market performance of publicly listed companies in the public health and healthcare sector in the A-share market [1] - The top ten weighted stocks in the National Index of Public Health and Healthcare as of February 28, 2025, include Mindray Medical, Hengrui Medicine, WuXi AppTec, and others, accounting for a total of 52.4% of the index [1] Group 2 - Guotai Junan Securities indicates that in 2024, external consumption and medical insurance environments are under pressure, leading to a decline in the unit price of specialized medical services such as ophthalmology and dentistry, resulting in slowed growth [2] - Despite the slowdown in revenue growth, the demand for medical services remains strong, and as the macro economy gradually recovers, residents' payment capabilities and consumer confidence are expected to improve, leading to a rebound in revenue growth [2] - The rapid development of AI technology is expected to bring significant changes to the healthcare industry, with the healthcare ETF Taikang (159760) likely to continue benefiting from this trend [2]